Search Results - "Atzpodien, Jens"

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group by Ettrich, Thomas J, Berger, Andreas W, Perkhofer, Lukas, Daum, Severin, König, Alexander, Dickhut, Andreas, Wittel, Uwe, Wille, Kai, Geissler, Michael, Algül, Hana, Gallmeier, Eike, Atzpodien, Jens, Kornmann, Marko, Muche, Rainer, Prasnikar, Nicole, Tannapfel, Andrea, Reinacher-Schick, Anke, Uhl, Waldemar, Seufferlein, Thomas

“…Even clearly resectable pancreatic cancer still has an unfavorable prognosis. Neoadjuvant or perioperative therapies might improve the prognosis of these…”
Get full text

Effects of Implementing a Brief Family Nursing Intervention With Hospitalized Oncology Patients and Their Families in Germany: A Quasi-Experimental Study by Zimansky, Manuel, Stasielowicz, Lukasz, Franke, Inga, Remmers, Hartmut, Friedel, Heiko, Atzpodien, Jens

“…Family nursing, based on the Calgary Family and Intervention Models, was implemented in a German oncological inpatient unit to promote effective family…”
Get full text

Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients by Atzpodien, Jens, Terfloth, Kerstin, Fluck, Michael, Reitz, Martina

“…Purpose The efficacy of cisplatin, gemcitabine, and treosulfan (CGT) was evaluated in patients with chemotherapy pretreated relapsed AJCC stage IV uveal…”
Get full text

Autoimmunity Resulting From Cytokine Treatment Predicts Long-Term Survival in Patients With Metastatic Renal Cell Cancer by FRANZKE, A, PEEST, D, PROBST-KEPPER, M, BUER, J, KIRCHNER, G. I, BRABANT, G, KIRCHNER, H, GANSER, A, ATZPODIEN, J

“…In patients undergoing cytokine therapy, systemically applied interleukin-2 (IL-2) and/or interferon-alpha (IFN-alpha) have been reported to induce thyroid…”
Get full text

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) by Modest, Dominik P., Martens, Uwe M., Riera-Knorrenschild, Jorge, Greeve, Jobst, Florschütz, Axel, Wessendorf, Swen, Ettrich, Thomas, Kanzler, Stephan, Nörenberg, Dominik, Ricke, Jens, Seidensticker, Max, Held, Swantje, Buechner-Steudel, Petra, Atzpodien, Jens, Heinemann, Volker, Seufferlein, Thomas, Tannapfel, Andrea, Reinacher-Schick, Anke C., Geissler, Michael

“…PURPOSE This trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in…”
Get full text

Predictive impact of retinoid X receptor-alpha-expression in renal-cell carcinoma by Buentig, Nicole, Stoerkel, Stefan, Richter, Eve, Dallmann, Iris, Reitz, Martina, Atzpodien, Jens

“…Retinoid receptors are nuclear transcription factors that mediate the effects of retinoids on gene expression. In our study, we analyzed the expression of…”
Get more information

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109) by Kurreck, Annika, Geissler, Michael, Martens, Uwe Marc, Riera-Knorrenschild, Jorge, Greeve, Jobst, Florschütz, Axel, Wessendorf, Swen, Ettrich, Thomas Jens, Kanzler, Stephan, Dominik, Nörenberg, Seidensticker, Max, Held, Swantje, Buechner-Steudel, Petra, Atzpodien, Jens, Heinemann, Volker, Stintzing, Sebastian, Seufferlein, Thomas, Tannapfel, Andrea, Reinacher, Anke, Modest, Dominik Paul

“…Abstract only e16055 Background: In patients with mCRC, dynamics of response and disease progression may play a critical role in the understanding of long-term…”
Get full text

Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109) by Modest, Dominik Paul, Noerenberg, Dominik, Seidensticker, Max, Ricke, Jens, Martens, Uwe Marc, Riera-Knorrenschild, Jorge, Greeve, Jobst, Florschütz, Axel, Wessendorf, Swen, Ettrich, Thomas Jens, Kanzler, Stephan, Held, Swantje, Buechner-Steudel, Petra, Atzpodien, Jens, Heinemann, Volker, Tannapfel, Andrea, Reinacher-Schick, Anke C., Geissler, Michael

“…Abstract only 3530 Background: The VOLFI trial demonstrated improved objective response rate (ORR) with the addition of pmab to modified triplet chemotherapy…”
Get full text

Abstract 2861: Independent validation of a prognostic gene-signature based risk score in formalin-fixed paraffin-embedded melanomas by Brunner, Georg, Heinecke, Achim, Suter, Ludwig, Blödorn-Schlicht, Norbert, Schulze, Hans-Joachim, Atzpodien, Jens

“…Abstract Current staging of melanoma, as defined in 2009 by the American Joint Committee on Cancer (AJCC), is based mainly on histopathological criteria but is…”
Get full text

A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging by Brunner, Georg, Heinecke, Achim, Falk, Thomas M, Ertas, Beyhan, Blödorn-Schlicht, Norbert, Schulze, Hans-Joachim, Suter, Ludwig, Atzpodien, Jens, Berking, Carola

“…Abstract Background Current clinico-pathological American Joint Committee on Cancer (AJCC) staging of primary cutaneous melanoma is limited in its ability to…”
Get full text

Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) by ATZPODIEN, J, KIRCHNER, H, BODENSTEIN, H, POMER, S, METZNER, B, REBMANN, U, OBERNEDER, R, SIEBELS, M, WANDERT, T, PUCHBERGER, T, REITZ, M, JONAS, U, BERGMANN, L, SCHOTT, H, HEYNEMANN, H, FORNARA, P, LOENING, S. A, ROIGAS, J, MÜLLER, S. C

“…We conducted a prospectively randomized clinical trial to compare the efficacy of three outpatient therapy regimens in 341 patients with progressive metastatic…”
Get full text

Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma by Atzpodien, Jens, Reitz, Martina

“…The aim of this study was to evaluate the prognostic impact of pretreatment neutrophils, previously rendered statistically independent, on the response and on…”
Get more information

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 by Marchand, Marie, van Baren, Nicolas, Weynants, Patrick, Brichard, Vincent, Dréno, Brigitte, Tessier, Marie‐Hélène, Rankin, Elaine, Parmiani, Giorgio, Arienti, Flavio, Humblet, Yves, Bourlond, André, Vanwijck, Romain, Liénard, Danielle, Beauduin, Marc, Dietrich, Pierre‐Yves, Russo, Vincenzo, Kerger, Joseph, Masucci, Giuseppe, Jäger, Elke, De Greve, Jacques, Atzpodien, Jens, Brasseur, Francis, Coulie, Pierre G., van der Bruggen, Pierre, Boon, Thierry

“…Thirty‐nine tumor‐bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE‐3.A1 peptide at monthly intervals. No…”
Get full text

Abstract 5070: Validation of a fresh-tissue based prognostic gene signature in formalin-fixed, paraffin-embedded melanomas by Brunner, Georg, Suter, Ludwig, Schulze, Hans-Joachim, Berking, Carola, Heinecke, Achim, Atzpodien, Jens

“…Abstract Melanoma incidence is rapidly increasing – with a doubling rate of 10-20 years. Precision and reliability of conventional histological and clinical…”
Get full text

Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients by Atzpodien, Jens, Morawek, Lars, Fluck, Michael, Reitz, Martina

“…Purpose To evaluate the efficacy of bleomycin, vinorelbine, and trofosfamide (BVT) in 28 patients with pretreated relapsed AJCC stage IV cutaneous malignant…”
Get full text

Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan by Atzpodien, Jens, Terfloth, Kerstin, Fluck, Michael, Reitz, Martina

“…We compared the efficacy and tolerability of cisplatin, gemcitabine, and treosulfan (CGT) therapy in younger patients (age, <60 years) and in elderly patients…”
Get full text

Abstract 4652: Identification and validation of a novel nine-gene signature predicting clinical outcome in malignant melanoma by Brunner, Georg, Heinecke, Achim, Reitz, Martina, Lippold, Andrea, Berking, Carola, Suter, Ludwig, Atzpodien, Jens

“…Abstract Incidence of malignant melanoma is rapidly increasing - with a doubling rate of 10-20 years. Conventional histopathological and clinical staging…”
Get full text

Long-term maintenance therapy in interferon-alpha2a/interleukin-2-pretreated advanced renal-cell carcinoma patients by Atzpodien, Jens, Reitz, Martina

“…In this paper, we report on the long-term therapeutic efficacy of maintenance treatment in 12 advanced renal carcinoma patients. Following prior systemic…”
Get more information

Does addition of 13-cis-retinoic acid to interferon-alpha2a improve survival in patients with metastatic RCC? by Atzpodien, Jens

Get full text

Does addition of 13- cis -retinoic acid to interferon-α2a improve survival in patients with metastatic RCC? by Atzpodien, Jens

Get full text